Robecosam AG Increases Stake in Cerner Co. (NASDAQ:CERN)

Robecosam AG boosted its stake in Cerner Co. (NASDAQ:CERN) by 0.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 346,483 shares of the company’s stock after purchasing an additional 2,586 shares during the period. Robecosam AG owned about 0.11% of Cerner worth $23,689,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in CERN. Wealthcare Advisory Partners LLC increased its stake in Cerner by 185.9% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 386 shares of the company’s stock worth $26,000 after purchasing an additional 251 shares during the period. Berman Capital Advisors LLC increased its stake in Cerner by 115.3% in the 2nd quarter. Berman Capital Advisors LLC now owns 381 shares of the company’s stock worth $27,000 after purchasing an additional 204 shares during the period. Altshuler Shaham Ltd increased its stake in Cerner by 173.2% in the 2nd quarter. Altshuler Shaham Ltd now owns 388 shares of the company’s stock worth $28,000 after purchasing an additional 246 shares during the period. CSat Investment Advisory L.P. increased its stake in Cerner by 119.7% in the 2nd quarter. CSat Investment Advisory L.P. now owns 637 shares of the company’s stock worth $47,000 after purchasing an additional 347 shares during the period. Finally, Valeo Financial Advisors LLC purchased a new position in Cerner in the 2nd quarter worth approximately $49,000. 82.69% of the stock is currently owned by institutional investors and hedge funds.

Shares of CERN stock opened at $67.76 on Friday. The firm has a market cap of $21.69 billion, a P/E ratio of 30.66, a P/E/G ratio of 2.12 and a beta of 0.93. Cerner Co. has a fifty-two week low of $48.78 and a fifty-two week high of $76.47. The business’s 50 day moving average price is $67.66 and its 200-day moving average price is $68.97. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.50 and a current ratio of 2.52.

Cerner (NASDAQ:CERN) last issued its quarterly earnings data on Wednesday, July 24th. The company reported $0.60 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.58 by $0.02. The firm had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.44 billion. Cerner had a return on equity of 15.14% and a net margin of 10.75%. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period last year, the company earned $0.62 EPS. As a group, equities analysts predict that Cerner Co. will post 2.44 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 9th. Investors of record on Wednesday, September 25th were given a dividend of $0.18 per share. The ex-dividend date of this dividend was Tuesday, September 24th. This represents a $0.72 annualized dividend and a dividend yield of 1.06%. Cerner’s dividend payout ratio is presently 32.58%.

In related news, Director Julie L. Gerberding sold 7,928 shares of Cerner stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $71.82, for a total transaction of $569,388.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Michael Nill sold 13,124 shares of Cerner stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $68.07, for a total value of $893,350.68. The disclosure for this sale can be found here. Insiders have sold 344,268 shares of company stock worth $23,243,010 over the last 90 days. 0.75% of the stock is currently owned by corporate insiders.

A number of brokerages have commented on CERN. Piper Jaffray Companies lifted their price target on Cerner from $74.00 to $80.00 and gave the stock an “overweight” rating in a research note on Thursday, July 25th. BidaskClub raised Cerner from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 25th. Wells Fargo & Co lifted their price target on Cerner from $72.00 to $80.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Cantor Fitzgerald lifted their price objective on Cerner from $75.00 to $85.00 and gave the stock an “overweight” rating in a research report on Monday, July 8th. Finally, ValuEngine lowered Cerner from a “buy” rating to a “hold” rating in a research report on Wednesday, September 4th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $75.19.

About Cerner

Cerner Corporation provides health care information technology solutions and tech-enabled services in the United States and internationally. The company offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers.

Featured Story: Diversification in Investing

Institutional Ownership by Quarter for Cerner (NASDAQ:CERN)

Receive News & Ratings for Cerner Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerner and related companies with MarketBeat.com's FREE daily email newsletter.